Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;31(3):870.
doi: 10.1007/s12032-014-0870-2. Epub 2014 Feb 8.

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer

Jasmine Miger  1 , Annika Holmqvist, Xiao-Feng Sun, Maria Albertsson
Affiliations

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer

Jasmine Miger et al. Med Oncol. 2014 Mar.

Abstract

The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n=35) with stage IV GI-cancer were included in the study and were divided into two groups; upper (n=13) and lower (n=22) GI-cancer. All patients were given continuous metronomic Xeloda (500 mg×2). Best response was measured by radiological and clinical examination including laboratory results. Standard RECIST criteria were used. Median age was 66 (range 29-86). Those patients who received first and second line had the longest duration of treatment. For patients with metastatic gastrointestinal cancer, metronomic capecitabine (Xeloda) may be beneficial both as far as tumor control and quality of life is concerned. In this pilot study, palliation for more than 2 years is observed for 6 of the 35 patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The number of patients in the two groups with upper and lower GI-cancer
Fig. 2
Fig. 2
Best response in both groups
Fig. 3
Fig. 3
Duration of treatment
See this image and copyright information in PMC

References

    1. Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579–588. doi: 10.1016/S1470-2045(12)70116-X. - DOI - PubMed
    1. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–4631. doi: 10.1200/JCO.2004.02.175. - DOI - PubMed
    1. Carstens H, Albertsson M. Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma. Acta Oncol. 2007;46(6):866–868. doi: 10.1080/02841860701203560. - DOI - PubMed
    1. Dahlberg M, Påhlman L, Bergström R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 2013;85(4):515–520. doi: 10.1046/j.1365-2168.1998.00603.x. - DOI - PubMed
    1. Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 2012;10(2):213–224. - PMC - PubMed

MeSH terms